Arrowhead Research reported $-1.36 in EPS Earnings Per Share for its fiscal quarter ending in June of 2026.


Fiscal Calendar Actual Consensus Previous Date
FY2026Q4 Sep/2025 -1.12 -0.11 Nov/30
FY2026Q3 Jun/2026 -1.36 -1.20 -1.26 Aug/04
FY2026Q2 Mar/2026 -0.93 -1.04 2.75 May/07
FY2026Q1 Dec/2025 0.22 0.04 -1.39 Feb/05
FY2025Q4 Sep/2025 -0.11 -0.23 -1.36 Nov/25




Eps Change Date
Agios Pharmaceuticals USD -1.69 0 Jun/2026
Alnylam Pharmaceuticals USD 1.84 0.15 Jun/2026
Anika Therapeutics USD 0.13 0.35 Dec/2025
Arrowhead Research USD -1.36 0.43 Jun/2026
Heron Therapeutics USD -0.02 0.02 Dec/2025
Incyte USD 3.09 1.28 Jun/2026
Ionis Pharmaceuticals USD -0.69 0.13 Jun/2026
Ligand Pharmaceuticals USD 1.63 0.39 Mar/2026
Merck USD -0.13 1.15 Jun/2026
Moderna USD -1.97 1.43 Jun/2026
Nektar Therapeutics USD -1.78 0.43 Mar/2026
Novartis USD 2.41 0.42 Jun/2026
Sarepta Therapeutics USD 3.16 6.74 Mar/2026
TG Therapeutics USD 0.05 0.07 Jun/2026
Ultragenyx Pharmaceutical USD -0.9 0.94 Jun/2026
Vertex Pharmaceuticals USD 4.73 0.26 Jun/2026
Xencor USD -1.71 1.62 Mar/2026